FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer

Oncology News Burst

Source: FDA Center for Drug Evaluation and Research - What's New - January 8, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news